Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Psychiatry Cardiology Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Emergency Medicine Ophthalmology Hematology Urology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Long QT syndrome

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for long QT syndrome

7 trials tracked for long QT syndrome: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 7 citations.

7Trials tracked

2Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 4 2 Phase 2 1 Phase 1 1 Other / NA 3

Phase 4 Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes Completed · 7 cited
Phase 4 Reducing the Risk of Drug-Induced QT Interval Lengthening in Women Completed
Phase 2 Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients Completed
Phase 1 Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function Completed
N/A Fetal and Neonatal Magnetophysiology Completed
N/A Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects Completed

Show 1 more trials

N/A Long QT Syndrome and Sleep Apnea Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Long QT syndrome: what the trials found

Clinical investigations into the management of long QT syndrome have evaluated hormonal and placebo interventions. In studies assessing testosterone, a significant increase in maximum rate-corrected QT interval (QTF) was observed following ibutilide administration (p=0.001), although the percentage change from pretreatment values did not reach statistical significance (p=0.60) ¹.

Progesterone administration also demonstrated a statistically significant increase in maximum post-ibutilide QT-F intervals (p=0.006). However, the percent change from baseline pre-ibutilide measurements was not significantly different (p=0.16) ². Placebo groups showed no significant changes in QTc duration at either 2 months (p=0.7958) or 6 months (p=0.3369) ³.

Recent results — preliminary, needs further review

Eleclazine is currently under investigation in a Phase 1 trial ⁴.
Continuous Positive Airway Pressure (CPAP) was evaluated regarding baseline QT interval, but results were not statistically significant ⁵.
Magnetocardiography was assessed for symptom experience and adverse events; however, concordance with postnatal ECG for diagnosis of long QT syndrome was limited ⁶.

For the clinician treating this condition

Both testosterone ¹ and progesterone ² were associated with significant increases in maximum post-ibutilide QT intervals, though the magnitude of change from baseline did not reach statistical significance in either case.
Placebo interventions showed no statistically significant changes in QTc duration over a 6-month period ³.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.